10x Genomics, Inc. (NASDAQ:TXG) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET
Company Participants
Cassie Corneau - Director-Investor Relations & Strategic Finance
Serge Saxonov - Chief Executive Officer and Co-Founder
Justin McAnear - Chief Financial Officer
Conference Call Participants
Daniel Arias - Stifel
Tejas Savant - Morgan Stanley
Madeline Mollman - Wolfe Research
Marta Zaremba - JPMorgan
Kyle Boucher - TD Cowen
Kyle Mikson - Canaccord Genuity
Michael Ryskin - Bank of America
Matthew Sykes - Goldman Sachs
Matt Larew - William Blair
Luke Sergott - Barclays
Operator
Thank you for standing by. My name is Kayla and I will be your conference operator today. At this time, I'd like to welcome everyone to the 10x Genomics' Second Quarter 2024 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instruction]
I would now like to turn the call over to Cassie Corneau, Director of Investor Relations and Strategic Finance. You may begin.
Cassie Corneau
Thank you and good afternoon, everyone. Earlier today, 10x Genomics released financial results for the second quarter ended June 30th, 2024. If you have not received this news release or if you would like to be added to the company's distribution list, please send an email to investors@10xgenomics.com. An archived webcast of this call will be available on the investor tab of the company's website 10xgenomics.com, for at least 45 days following this call.
Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated, and you should not place undue reliance on forward-looking statements.
Additional information regarding these risks, uncertainties and factors that could cause results to differ appears in the press release 10x Genomics issued today and in the documents and reports filed by 10x Genomics from time to time with the Securities and Exchange Commission. 10x Genomics disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether because of new information, future events or otherwise.
Joining the call today are Serge Saxonov, our CEO and Co-Founder, and Justin McAnear, our Chief Financial Officer. We will host a question-and-answer session after our prepared remarks. We ask analysts to please keep to one question, so that we may accommodate everyone in the queue.